UC Davis Researchers Synthesized Modified LSD Compounds
Scientists created nine LSD variations to explore potential medical uses while reducing harmful side effects.
Updated on Sept. 18, 2026 in Chemistry
Live Poll
Should scientists focus on modifying existing psychedelic drugs to create new medical treatments?
Researchers at the University of California, Davis have synthesized nine modified versions of LSD by removing parts of the drug's core molecular structure. The study aims to isolate therapeutic benefits while eliminating hallucinogenic and toxic properties.
Why it matters
This work seeks to develop new medicines derived from psychedelics that can treat conditions without the harmful side effects associated with traditional hallucinogens. By simplifying the chemical framework, researchers hope to create safer therapeutic compounds.
Researchers synthesized nine modified versions of LSD by systematically altering the ergoline core, which normally contains four fused molecular rings. They identified phenethylamine-like features as the primary drivers of hallucinogenic activity.
The players
University of California, Davis
This public research university serves as a major hub for scientific innovation and academic studies in California.
Proceedings of the National Academy of Sciences
This peer-reviewed journal is one of the world's most-cited and comprehensive multidisciplinary scientific serials.
The details
The team successfully produced two compounds, UCD0094 and UCD0076, that showed improved safety profiles by reducing cardiotoxic and hallucinogenic effects. Specifically, UCD0076 displayed a binding preference for the 5-HT2C serotonin receptor and induced antipsychotic-like effects in mice.
Timeline
The study was published in the Proceedings of the National Academy of Sciences on September 8, 2026.
The Big Picture
This discovery updates the methodology used in the ongoing development of non-hallucinogenic psychedelic-inspired therapeutics. By deconstructing the ergoline core, the study shifts the paradigm toward creating synthetic derivatives with targeted biological effects.
These findings could eventually lead to the development of new, effective antipsychotic medications with fewer side effects than current prescriptions. While these compounds are currently in early testing stages, they provide a blueprint for future pharmaceutical innovation.
The takeaway
The research highlights that it is possible to decouple the therapeutic potential of psychedelics from their psychoactive effects through targeted molecular modification. Future clinical drug development will likely utilize these simplified compounds as essential starting points.
Further reading
For more information on molecular innovations, visit the Chemistry section.
More information
Read the journal study on LSD deconstruction for detailed chemical analysis.
Source note: This article includes information reported by SciTechDaily.
Live Poll
Should scientists focus on modifying existing psychedelic drugs to create new medical treatments?
